Serotonin reuptake inhibitor antidepressants and abnormal bleeding: A review for clinicians and a reconsideration of mechanisms

Journal of Clinical Psychiatry

Volumn 71, Issue 12, 2010, Pages 1565-1575

  Andrade, Chittaranjan ^a   Sandarsh, Surya ^a   Chethan, Kumar B ^a   Nagesh, Koregala S ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLOMIPRAMINE; CLOPIDOGREL; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; WARFARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG MECHANISM; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MEDICAL LITERATURE; MEDLINE; MENSTRUATION; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; STOMACH ACID SECRETION; SYSTEMATIC REVIEW; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COMORBIDITY; FIBROSIS; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; LIVER FAILURE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 78650500543     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09r05786blu     Document Type: Article

References (72)

1. Andrade C. Psychopharmacology. In: Bhugra D, Ranjith G, Patel V, eds. Handbook of Psychiatry: A South Asian Perspective. New Delhi, India: Byword Publishers; 2005:517-552.
2. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65(12):1642-1653.
3. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106-1109.
4. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323(7314):655-658.
5. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59-64.
6. Meijer WEE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164(21):2367-2370.
7. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005;22(3):175-181.
8. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23(7):937-944.
9. Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol. 2007;63(4):403-408. (Pubitemid 46399132)
10. Ziegelstein RC, Meuchel J, Kim TJ, et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med. 2007;120(6):525-530.
11. de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65(7):795-803.
12. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 2008;66(1):76-81.
13. Vidal X, Ibáñez L, Vendrell L, et al; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf. 2008;31(2):159-168.
14. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104(6):1475-1482.
15. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009;7(12):1314-1321.
16. Barbui C, Andretta M, De Vitis G, et al. Antidepressant drug prescription and risk of abnormal bleeding: a case-control study. J Clin Psychopharmacol. 2009;29(1):33-38.
17. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31-40. (Pubitemid 350212624)
18. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119(2):113-116.
19. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59.
20. Hougardy DM, Egberts TC, van der Graaf F, et al. Serotonin transporter polymorphism and bleeding time during SSRI therapy. Br J Clin Pharmacol. 2008;65(5):761-766.
21. McCloskey DJ, Postolache TT, Vittone BJ, et al. Selective serotonin re-uptake inhibitors: measurement of effect on platelet function. Transl Res. 2008;151(3):168-172.
22. Abdel Salam OM. Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats. Pharmacol Res. 2004;50(3):309-316.
23. Yamaguchi T, Hidaka N, Suemaru K, et al. The coadministration of paroxetine and low-dose aspirin synergistically enhances gastric ulcerogenic risk in rats. Biol Pharm Bull. 2008;31(7):1371-1375. (Pubitemid 351930649)
24. de Jong JC, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003;55(6):591-595.
25. Zullino DF, Khazaal Y. Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions. Br J Clin Pharmacol. 2005;59(1):118-119, author reply 119.
26. de Jong JCF, Brouwers JRBJ, de Jong-van den Berg LTW. Combined use of NSAIDs and SSRIs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2005;59(1):119.
27. Pedrazza EL, Senger MR, Rico EP, et al. Fluoxetine and nortriptyline affect NTPDase and 5′-nucleotidase activities in rat blood serum. Life Sci. 2007;81(15):1205-1210.
28. Finkel MS, Laghrissi-Thode F, Pollock BG, et al. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 1996;32(4):653-658.
29. Krejcy K, Schmetterer L, Kastner J, et al. Role of nitric oxide in hemostatic system activation in vivo in humans. Arterioscler Thromb Vasc Biol. 1995;15(11):2063-2067.
30. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006;26(9):1307-1313.
31. Serebruany VL, Glassman AH, Malinin AI, et al; Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108(8):939-944.
32. Serebruany VL, Suckow RF, Cooper TB, et al; Sertraline Antidepressant Heart Attack Randomized Trial. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry. 2005;162(6):1165-1170.
33. Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med. 2008;168(2):180-185. (Pubitemid 351185885)
34. Wallerstedt SM, Gleerup H, Sundström A, et al. Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18(5):412-416.
35. Hauta-Aho M, Tirkkonen T, Vahlberg T, et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med. 2009;41(8):619-628.
36. Kim DH, Daskalakis C, Whellan DJ, et al. Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol. 2009;103(10):1391-1395.
37. Kotzailias N, Andonovski T, Dukic A, et al. Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial. J Clin Pharmacol. 2006;46(4):468-475.
38. Shen WW, Swartz CM, Calhoun JW. Is inhibition of nitric oxide synthase a mechanism for SSRI-induced bleeding? Psychosomatics. 1999;40(3):268-269.
39. Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol. 2000;10(1):35-38.
40. Duijvestijn YC, Kalmeijer MD, Passier AL, et al. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine. Br J Clin Pharmacol. 2003;56(5):581-582.
41. Sharma RC. Escitalopram-induced subconjunctival hemorrhage: a case report. Prim Psychiatry. 2009;16:29-30.
42. de Abajo FJ, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2000;50(1):43-47.
43. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049-3051.
44. Movig KL, Janssen MW, de Waal Malefijt J, et al. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med. 2003;163(19):2354-2358.
45. Andreasen JJ, Riis A, Hjortdal VE, et al. Effect of selective serotonin reuptake inhibitors on requirement for allogeneic red blood cell transfusion following coronary artery bypass surgery. Am J Cardiovasc Drugs. 2006;6(4):243-250. (Pubitemid 44285133)
46. Van Cann EM, Koole R. Abnormal bleeding after an oral surgical procedure leading to airway compromise in a patient taking a selective serotonin reuptake inhibitor and a nonsteroidal antiinflammatory drug. Anesthesiology. 2008;109(3):568-569.
47. Smith M, Robinson D. Sertraline and vaginal bleeding - a possible association. J Am Geriatr Soc. 2002;50(1):200-201.
48. Linnebur SA, Saseen JJ, Pace WD. Venlafaxine-associated vaginal bleeding. Pharmacotherapy. 2002;22(5):652-655.
49. Palmer TR. Sertraline and vaginal bleeding - a possible association? J Am Geriatr Soc. 2003;51(2):279.
50. Ekstedt B, Pakbaz M, Gärskog O, et al. [SSRI during pregnancy can cause bleeding complications] [article in Swedish]. Lakartidningen. 2007;104(14-15):1145-1146.
51. Salkeld E, Ferris LE, Juurlink DN. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol. 2008;28(2):230-234.
52. Maayan-Metzger A, Kuint J, Lubetsky A, et al. Maternal selective serotonin reuptake inhibitor intake does not seem to affect neonatal platelet function tests. Acta Haematol. 2006;115(3-4):157-161.
53. Saldanha D, Kumar N, Ryali VSSR, et al. Serum serotonin abnormality in depression. MJAFI. 2009;65:108-112.
54. Cordeaux Y, Pasupathy D, Bacon J, et al. Characterization of serotonin receptors in pregnant human myometrium. J Pharmacol Exp Ther. 2009;328(3):682-691.
55. Weinrieb RM, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry. 2003;64(12):1502-1510.
56. Martin KA, Krahn LE, Balan V, et al. Selective serotonin reuptake inhibitors in the context of hepatitis C infection: reexamining the risks of bleeding. J Clin Psychiatry. 2007;68(7):1024-1026. (Pubitemid 47340321)
57. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 1996;153(10):1313-1317.
58. 2A receptor as missing link? Psychosom Med. 2003;65(5):729-737.
59. Jiang W, Glassman A, Krishnan R, et al. Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J. 2005;150(1):54-78.
60. Pizzi C, Mancini S, Angeloni L, et al. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86(5):527-532.
61. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104(16):1894-1898.
62. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108(1):32-36.
63. Taylor CB, Youngblood ME, Catellier D, et al; ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-798. (Pubitemid 41002762)
64. Meier, CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179-184.
65. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33(6):1465-1473.
66. Barbui C, Percudani M, Fortino I, et al. Past use of selective serotonin reuptake inhibitors and the risk of cerebrovascular events in the elderly. Int Clin Psychopharmacol. 2005;20(3):169-171.
67. Bilici M, Ozturk C, Dursun H, et al. Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. Dig Dis Sci. 2009;54(9):1868-1875.
68. Dursun H, Bilici M, Albayrak F, et al. Antiulcer activity of fluvoxamine in rats and its effect on oxidant and antioxidant parameters in stomach tissue. BMC Gastroenterol. 2009;9(1):36.
69. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5(4):401-412.
70. Tuomisto J, Tukiainen E, Ahlfors UG. Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology (Berl). 1979;65(2):141-147. (Pubitemid 10226365)
71. Le Quan-Bui KH, Plaisant O, Leboyer M, et al. Reduced platelet serotonin in depression. Psychiatry Res. 1984;13(2):129-139.
72. Maurer-Spurej E, Pittendreigh C, Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci. 2007;32(1):23-29.